Immuno-oncology insights最新文献_第3页

New tools for spatial biology transcriptomics & proteomics in immuno-oncology 免疫肿瘤学中空间生物学转录组学和蛋白质组学的新工具

Immuno-oncology insights Pub Date : 2023-04-19 DOI: 10.18609/ioi.2023.005

Mario Flores

引用次数: 0

Addressing the complexity of the TME with organoids 用类器官解决TME的复杂性

Immuno-oncology insights Pub Date : 2023-04-18 DOI: 10.18609/ioi.2023.015

E. De Braekeleer

引用次数: 0

Assessing efficacy & MoA of mono & combo immunotherapies in preclinical humanized models 评估单一和联合免疫疗法在临床前人源化模型中的疗效和MoA

Immuno-oncology insights Pub Date : 2023-04-18 DOI: 10.18609/ioi.2023.003

K. Thiam, A. Surya, E. H. van der Horst

{"title":"Assessing efficacy & MoA of mono & combo immunotherapies in preclinical humanized models","authors":"K. Thiam, A. Surya, E. H. van der Horst","doi":"10.18609/ioi.2023.003","DOIUrl":"https://doi.org/10.18609/ioi.2023.003","url":null,"abstract":"The breakthrough of immune checkpoint-targeting therapies has unveiled new hopes for cancer therapy. However, subsets of patients who do not see robust responses to immunotherapy remain. To address this hurdle, combination therapies – coupling agents with distinct mechanisms of action (MoA) – appear promising to enhance treatment success against various cancers. However, a major challenge in the development of novel combination therapies is the unmet need for preclinical models to predict efficacy and tolerability. Immunocompetent models featuring humanized immune checkpoints enable the assessment of human-targeted therapies in well-established syngeneic tumor models, allowing investigation with fully functional crosstalk among syngeneic tumor, immune, and stromal cells. While these models enable profiling evaluation of agents directed toward human targets, results still reflect mouse biology. Alternatively, immunodeficient mice reconstituted with a human immune system offer the possibility to investigate the efficacy and MoA of agents directed against human targets, with the advantage of exploring human biology using human tumor cell lines in a mouse model. This article discusses examples of applicability and complementarity of syngeneic and BRGSF– human immune system (HIS) models to assess the efficacy and MoA of immunotherapies, either in combination with inhibitory immune checkpoints or as monotherapy.","PeriodicalId":73351,"journal":{"name":"Immuno-oncology insights","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41806688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Considering the nonclinical toolkit in I–O: assessing safety, understanding the TME & working towards an animal-free future 考虑I/O中的非临床工具包：评估安全性，了解TME并努力实现无动物的未来

Immuno-oncology insights Pub Date : 2023-04-18 DOI: 10.18609/ioi.2023.011

Kimberly Homan, Aaron M. Fullerton

引用次数: 0

Looking for the bigger picture: current challenges & progress in preclinical tools for I–O 放眼全局:I-O临床前工具的当前挑战和进展

Immuno-oncology insights Pub Date : 2023-04-18 DOI: 10.18609/ioi.2023.001

P. Candarlioglu

引用次数: 0

AI-driven image analysis for cancer cell biology 用于癌细胞生物学的人工智能驱动图像分析

Immuno-oncology insights Pub Date : 2023-04-15 DOI: 10.18609/ioi.2023.007

Gillian F. Lovell